Detection of a large unnamed Babesia piroplasm originally identified in dogs in North Carolina in a dog with no history of travel to that state
Authors:
- Patricia J. HolmanPHPatricia J. Holman
- Brianna B. BacklundBBBrianna B. Backlund
- Angela L. WilcoxAWAngela L. Wilcox
- Richard StoneRSRichard Stone
- Andrew L. StricklinASAndrew L. Stricklin
- Kendall E. BardinKBKendall E. Bardin
- 1 October 2009
- journal article
- case report
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 235 (7) , 851-854
Abstract
Case Description—A 12-year-old 46-kg (101.2-lb) sexually intact male Labrador Retriever was evaluated because of lymphadenomegaly. The dog resided in Texas, and its travel history included many southeastern and eastern shore states but not North Carolina. Clinical Findings—Following evaluation of the dog, a diagnosis of stage IVa intermediate- to large-cell lymphoma was made. A cyclophosphamide-hydroxydaunorubicin (doxorubicin)-vincristine-prednisone chemotherapy protocol was initiated. One week after the first chemotherapeutic treatment, a routine blood smear evaluation revealed single and paired intraerythrocytic large piroplasms that resembled Babesia canis. Via molecular testing, the organism was identified as a Babesia sp that had been detected previously in dogs in North Carolina. Treatment and Outcome—The dog was administered imidocarb diproprionate (7 mg/kg [3.2 mg/lb], IM) on 2 occasions (3-week interval). At 1, 4, 15, and 50 weeks after the second treatment, blood samples were analyzed specifically for the North Carolina Babesia sp via PCR assay; the result of each assay was positive. Clinical Relevance—Because of the morphologic similarity of the large piroplasm detected in dogs in North Carolina to B canis, molecular testing of large piroplasms detected in dogs is needed to definitively identify the infective Babesia sp. In the dog of this report, the infection was not eliminated following treatment with imidocarb diproprionate, which may have been a result of the immunocompromised state of the dog or the drug's ineffectiveness against this parasite. If imidocarb diproprionate is ineffective against the North Carolina Babesia sp, treated dogs may act as reservoirs of infection.Keywords
This publication has 9 references indexed in Scilit:
- In vitro cultivation of a newly recognized Babesia sp. in dogs in North CarolinaVeterinary Parasitology, 2008
- Blood, Bull Terriers and Babesiosis: further evidence for direct transmission of Babesia gibsoni in dogsAustralian Veterinary Journal, 2007
- Babesia gibsoni: Detection during experimental infections and after combined atovaquone and azithromycin therapyExperimental Parasitology, 2007
- Sequence polymorphism in the ribosomal DNA internal transcribed spacers differs among Theileria speciesVeterinary Parasitology, 2007
- Babesia conradae, sp. Nov., a small canine Babesia identified in CaliforniaVeterinary Parasitology, 2006
- Detection and molecular characterization of a novel large Babesia species in a dogVeterinary Parasitology, 2004
- Efficacy of atovaquone against Babesia gibsoni in vivo and in vitroVeterinary Parasitology, 2004
- Ribosomal RNA analysis of Babesia odocoilei isolates from farmed reindeer ( Rangifer tarandus tarandus ) and elk ( Cervus elaphus canadensis ) in WisconsinParasitology Research, 2003
- There are at least three genetically distinct small piroplasms from dogsInternational Journal for Parasitology, 2000